Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
AI Model Surpasses Radiologists in Detecting Subtle Hip Fractures
A new AI model outperformed radiologists in identifying difficult-to-detect femoral neck fractures on radiographs.
•Radiology Business
UCLA Review Evaluates Breast AI for Early Cancer Detection
A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.
•AuntMinnie
AI-Driven Whole-Body MRI Biomarkers Aid Myeloma Risk Stratification
AI-powered MRI analysis offers automated risk stratification via body composition in multiple myeloma patients.